Logo image of AVCO

AVALON GLOBOCARE CORP (AVCO) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:AVCO - US05344R1041 - Common Stock

0.5259 USD
-0.1 (-16.52%)
Last: 11/9/2022, 8:00:00 PM
0.601 USD
+0.08 (+14.28%)
After Hours: 11/9/2022, 8:00:00 PM

AVCO Key Statistics, Chart & Performance

Key Statistics
Market Cap46.82M
Revenue(TTM)1.41M
Net Income(TTM)-8.46M
Shares89.03M
Float37.78M
52 Week High1.07
52 Week Low0.38
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.1
PEN/A
Fwd PEN/A
Earnings (Next)11-22 2022-11-22/amc
IPO2016-02-22
Sector
GICS SectorReal Estate
GICS IndustryReal Estate Management & Development
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)


AVCO short term performance overview.The bars show the price performance of AVCO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

AVCO long term performance overview.The bars show the price performance of AVCO in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of AVCO is 0.5259 USD. In the past month the price increased by 4.7%. In the past year, price decreased by -49.43%.

AVALON GLOBOCARE CORP / AVCO Daily stock chart

AVCO Competitors/Peers

The largest stocks on the US markets in the "Real Estate Operating Companies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LB LANDBRIDGE CO LLC-A 36.83 3.78B
KW KENNEDY-WILSON HOLDINGS INC N/A 1.33B
TCI TRANSCONTINENTAL REALTY INV 90.18 506.48M
FRPH FRP HOLDINGS INC 67.03 435.74M
MLP MAUI LAND & PINEAPPLE CO N/A 334.40M
ARL AMERICAN REALTY INVESTORS IN 44.61 259.37M
OZ BELPOINTE PREP LLC- CLASS A N/A 252.97M
SEG SEAPORT ENTERTAINMENT GROUP N/A 251.87M
SRG SERITAGE GROWTH PROP- A N/A 183.04M
LPA LOGISTIC PROPERTIES OF THE A 12.41 86.05M
MAYS MAYS (J.W.) INC N/A 80.68M
INTG INTERGROUP CORP N/A 61.04M

About AVCO

Company Profile

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm provides immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics, and therapeutics. The company operates through two segments: real property and medical related consulting services. Its major clinical programs include AVA-001, AVA-011 and FLASH-CAR, ACTEX, and AVA-Trap. The company also provides strategic advisory and outsourcing services to facilitate and enhance its client's growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its services include research studies, executive education, daily online executive briefings, expert advisory services, and consulting and management services.

Company Info

AVALON GLOBOCARE CORP

4400 ROUTE 9, SUITE 3100

Freehold NEW JERSEY 07728 US

CEO: David Jin

Employees: 5

AVCO Company Website

Phone: 17327804400.0

AVALON GLOBOCARE CORP / AVCO FAQ

What does AVALON GLOBOCARE CORP do?

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm provides immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics, and therapeutics. The company operates through two segments: real property and medical related consulting services. Its major clinical programs include AVA-001, AVA-011 and FLASH-CAR, ACTEX, and AVA-Trap. The company also provides strategic advisory and outsourcing services to facilitate and enhance its client's growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its services include research studies, executive education, daily online executive briefings, expert advisory services, and consulting and management services.


Can you provide the latest stock price for AVALON GLOBOCARE CORP?

The current stock price of AVCO is 0.5259 USD. The price decreased by -16.52% in the last trading session.


What is the dividend status of AVALON GLOBOCARE CORP?

AVCO does not pay a dividend.


What is the ChartMill rating of AVALON GLOBOCARE CORP stock?

AVCO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the sector and industry classification for AVALON GLOBOCARE CORP?

AVALON GLOBOCARE CORP (AVCO) operates in the Real Estate sector and the Real Estate Management & Development industry.


What is the market capitalization of AVCO stock?

AVALON GLOBOCARE CORP (AVCO) has a market capitalization of 46.82M USD. This makes AVCO a Nano Cap stock.


Can you provide the ownership details for AVCO stock?

You can find the ownership structure of AVALON GLOBOCARE CORP (AVCO) on the Ownership tab.


AVCO Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to AVCO. When comparing the yearly performance of all stocks, AVCO is a bad performer in the overall market: 80.4% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AVCO Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AVCO. AVCO may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AVCO Financial Highlights

Over the last trailing twelve months AVCO reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 27.93% compared to the year before.


Industry RankSector Rank
PM (TTM) -600.07%
ROA -82.31%
ROE N/A
Debt/Equity 14
Chartmill High Growth Momentum
EPS Q2Q%18.38%
Sales Q2Q%3.78%
EPS 1Y (TTM)27.93%
Revenue 1Y (TTM)5.16%

AVCO Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

AVCO Ownership

Ownership
Inst OwnersN/A
Ins Owners66.28%
Short Float %N/A
Short RatioN/A